UNSPSC 51111653: Tocladesine

This classification denotes a purine antagonist and differentiation inducer with the molecular formula C10H11ClN5O6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BQ94Z7E5OR, chemically known as 8-chloroadenosine 3,5-monophosphate but generally known as tocladesine, which bears US NIH Compound Identifier 100299. Most nations schedule tocladesine under HS 29349990 and SITC 51579. As of Q4 2014, TOCLADESINE remains the US FDA Preferred Term for this commodity.

Tocladesine bears US NLM identifiers UMLS ID C0050063 and NCI Concept Code C2571. SMILES: C1C2C(C(C(O2)N3C4=C(C(=NC=N4)N)N=C3CL)O)OP(=O)(O1)O.

UNSPSC 51111653 Tocladesine, a Commodity code, reflects state and local procurement of this pharmaceutical product, though recent solicitation activity under the code is limited and indirect. The Texas Health and Human Services Commission issued a Request for Information (RFI) in April 2026 — RFI No. HHS0017013 — seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program. The RFI does not solicit tocladesine specifically but rather gathers market intelligence on vendors' capacity to establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management. State and local governments procure pharmaceuticals through multiple channels: traditional pharmacy benefit manager (PBM) arrangements, group purchasing organizations (GPOs), wholesalers, and increasingly through direct-to-manufacturer contracting models. The Texas RFI signals a shift toward direct procurement pathways that bypass traditional intermediaries, requesting vendor experience with self-insured employer and government health plan contracting, negotiated net pricing without rebates, and value-based or outcomes-based agreements. The issuing body is a state health agency, specifically the Texas HHS Commission, though the RFI's exploratory nature and broad vendor outreach suggest potential application across multiple state jurisdictions and government employee and retiree plans.

Recent solicitation activity under this code centers on Texas, with the April 2026 RFI serving as a preliminary market assessment rather than a formal competitive procurement with binding timelines, budget allocations, or set-aside designations. The RFI is designed to inform future procurement strategy before the state issues a formal Request for Proposal (RFP), meaning that substantive contracting activity for specific pharmaceuticals like tocladesine has not yet materialized under the new direct-to-manufacturer model. No award values, response details from vendors, or follow-on procurement timelines are specified in current materials. The limited recent activity suggests that tocladesine procurement opportunities under this code may remain minimal until the state completes the RFI phase and transitions to formal competitive solicitations with defined specifications and pricing structures.